Literature DB >> 3315038

The 5q- abnormality.

S D Nimer1, D W Golde.   

Abstract

Mesh：

Substances：

Year:  1987        PMID： 3315038

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  21 in total

1.  The 5q- syndrome: biology and treatment.

Authors:  Eric Padron; Rami Komrokji; Alan F List
Journal:  Curr Treat Options Oncol       Date:  2011-12

Review 2.  Acute myelogenous leukaemia in children.

Authors:  S O Lie
Journal:  Eur J Pediatr       Date:  1989-02       Impact factor: 3.183

3.  NPM1 gene deletions in myelodysplastic syndromes with 5q- and complex karyotype.

Authors:  Emanuele Ammatuna; Paola Panetta; Xabier Agirre; Tiziana Ottone; Serena Lavorgna; Maria José Calasanz; Francesco Lo-Coco
Journal:  Haematologica       Date:  2011-03-10       Impact factor: 9.941

4.  The nature and evolving treatment of myelodysplastic syndromes.

Authors:  P Greenberg
Journal:  West J Med       Date:  1989-08

Review 5.  Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy.

Authors:  Klaus Strebhardt
Journal:  Nat Rev Drug Discov       Date:  2010-08       Impact factor: 84.694

6.  Cloning of the gene coding for human class 1 heparin-binding growth factor and its expression in fetal tissues.

Authors:  W P Wang; K Lehtoma; M L Varban; I Krishnan; I M Chiu
Journal:  Mol Cell Biol       Date:  1989-06       Impact factor: 4.272

7.  Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map.

Authors:  N Zhao; A Stoffel; P W Wang; J D Eisenbart; R Espinosa; R A Larson; M M Le Beau
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

Review 8.  The colony stimulating factors.

Authors:  M Hansson; T Söderström
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

9.  Genetic mapping of tumor susceptibility genes involved in mouse plasmacytomagenesis.

Authors:  B A Mock; M M Krall; J K Dosik
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

10.  The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?

Authors:  Hagop Kantarjian; Susan O'Brien; Farhad Ravandi; Gautam Borthakur; Stefan Faderl; Carlos Bueso-Ramos; Lynne Abruzzo; Sherry Pierce; Jianqin Shan; Jean-Pierre Issa; Guillermo Garcia-Manero
Journal:  Cancer       Date:  2009-11-15       Impact factor: 6.860
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.